Validea Joel Greenblatt Strategy Daily Upgrade Report

Validea’s Earnings Yield Investor model, which follows Joel Greenblatt’s ‘Magic Formula’ of high return on capital and earnings yield, upgraded a slate of stocks after reassessing fundamentals and valuation: Playtika (PLTK) rose to 100% (pass), while Catalyst Pharmaceuticals (CPRX), Pediatrix Medical (MD), Match Group (MTCH) and Frontdoor (FTDR) were boosted to ~90% and flagged as passes; Clorox (CLX), Adeia (ADEA) and Cimpress (CMPR) moved to ~80% but failed the model’s final ranking, and ASGN (ASGN) also reached 80% but failed. The report notes that most names show neutral earnings-yield and return-on-tangible-capital signals, suggesting the upgrades were driven mainly by valuation shifts within the model’s framework and may provide a short list of value-oriented ideas for quant/value-focused portfolios.

Analysis

Validea's Earnings Yield Investor model, which implements Joel Greenblatt's Magic Formula (high return on capital and earnings yield), revised ratings across a nine-name slate: Playtika (PLTK) moved to 100% (Final Ranking: PASS), Catalyst Pharmaceuticals (CPRX) 50%→90% (PASS), Pediatrix Medical (MD) 40%→90% (PASS), Match Group (MTCH) 30%→90% (PASS), Frontdoor (FTDR) 40%→90% (PASS), while Clorox (CLX) 60%→80% (FAIL), Adeia (ADEA) 40%→80% (FAIL), Cimpress (CMPR) 60%→80% (FAIL) and ASGN 10%→80% (FAIL). The report's per-stock tables show earnings-yield and return-on-tangible-capital flags as predominantly NEUTRAL, indicating the model's upgrades were driven more by relative valuation movements within the formula than by clear improvements in the two core fundamentals.

Model-level sentiment and market-impact metrics are mildly positive but low (sentiment_score 0.25, market_impact_score 0.25), suggesting these changes are a screening signal rather than a market-moving event. High-scoring names (PLTK, CPRX, MD, MTCH, FTDR) merit further bottom-up diligence because the strategy signals interest but the underlying earnings-yield/ROTC neutrality implies earnings or capital-efficiency catalysts must be validated. Names that improved to ~80% but failed the final ranking (CLX, ADEA, CMPR, ASGN) represent valuation-driven crossovers that failed other weighted criteria and should be treated cautiously until fundamentals confirm the signal.

Key Decisions for Investors

• Consider screening the PASS names (PLTK, CPRX, MD, MTCH, FTDR) for selective, modest-sized exposure but perform immediate bottom-up checks on earnings yield, return-on-tangible-capital and near-term catalysts before adding positions
• Defer adding or reduce exposure to the upgraded-but-FAILED names (CLX, ADEA, CMPR, ASGN) until the model's core fundamentals (earnings yield or ROTC) show improvement or the firm-specific valuation drivers are validated
• Treat Validea's list as a quantitative starting point rather than a buy signal: require corroborating earnings revisions, cash-flow trends or commercial/regulatory updates (particularly for CPRX) before increasing conviction
• Because overall market-impact is mild and sentiment is only modestly positive, manage position sizing and set explicit stop-loss or hedges to protect against reversals if fundamentals do not follow the valuation-driven upgrade